gebhart/patrepeval huggingface dataset:
Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction (2003)

Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which is synthesized in the liver and circulates in the blood at a concentration of about 275 nmol/l. Once activated, by thrombin or plasmin, TAFI down regulates fibrinolysis, slowing clot lysis by cleaving the C-terminal lysine and arginine residues from partially degraded fibrin. Thrombomodulin enhances thrombin activation of TAFI by more than 1000-fold, suggesting that the thrombin-thrombomodulin complex is the physiological activator of TAFI. Activated protein C can up-regulate fibrinolysis by limiting the activation of TAFI via the attenuation of thrombin production. While impairment of fibrinolysis may predispose to thrombosis, excessive fibrinolysis may result in a bleeding tendency. In acquired coagulopathies, TAFI antigen levels are reduced in patients with disseminated intravascular coagulation. In focusing on women with major post-partum haemorrhage requiring blood transfusion, a significant reduction in TAFI levels is observed. The precise degree of TAFI activation is currently being characterized using new and more specific assays. The resulting data may provide insight into therapeutic options to treat post-partum haemorrhage, which is associated with significant morbidity.
Kinetic Analysis of Central [76Br]Bromolisuride Binding to Dopamine D2 Receptors Studied by PET (1991)

The in vivo kinetic analysis of dopamine D2 receptors was obtained in baboon brain using positron emission tomography (PET) and [76Br]bromolisuride [( 76Br]BLIS) as radioligand. An injection of a trace amount of [76Br]BLIS was followed 3 h later by an injection of a mixture of [76Br]BLIS and BLIS in the same syringe (coinjection experiment). A third injection performed at 6 h was either an excess of unlabeled ligand (displacement experiment) or a second coinjection. This protocol allowed us to evaluate in the striatum of each animal and after a single experiment the quantity of available receptors (B'max) and the kinetic parameters including the association and dissociation rate constants (k + 1VR and k-1, respectively, where VR is the volume of reaction). The cerebellum data were fitted using a model without specific binding. All the parameters were estimated using nonlinear mathematical models of the ligand-receptor interactions including or not including nonspecific binding. The plasma time-concentration curve was used as an input function after correction for the metabolites. An estimate of standard errors was obtained for each PET study and for each identified parameter using the covariance matrix. The average values of B'max and KdVR were 73 +/- 11 pmol/ml tissue and 1.9 +/- 0.9 pmol/ml, respectively. The nonspecific binding was identifiable in the experiment where the last injection corresponded to a second coinjection. We found that approximately 6% of the striatal binding was nonspecific after a tracer injection of [76Br]BLIS. The nonspecific binding appeared to be reversible in the striatum but irreversible in the cerebellum.
Phase-Coupled Plasmon-Induced Transparency (2010)

We demonstrate the existence of electromagnetically-induced-transparency (EIT-)like spectral response in a system of nanoscale plasmonic resonator antennas coupled by means of a single-mode silicon waveguide. Our proposed scheme exploits the phase of the coupling between the antennas in contrast with the existing plasmonic approaches that rely on the strength of direct, near-field coupling of nanometallic elements. Quality factors of over 100 and group indices of over 10 are readily achieved at near-infrared frequencies by a single unit in ≈1 μm2 of total device footprint, representing a more than two orders size reduction over corresponding dielectric EIT structures. By obviating the need for a near-field interaction, the phase-coupling scheme also facilitates an improved access to the coupling medium between the resonators thereby paving the way toward dynamic control of their sharp EIT-like spectral response.
Short-circuit memory in electrochromic displays (1980)

We prove that direct matrix addressing of electrochromic displays is theoretically possible if an appropriate free-energy barrier for charge transfer across the electrode/electrolyte interface can be introduced. We derive the maximum short-circuit memory of such an electrochromic cell in terms of its intrinsic response time. For response times ∼10 msec and electrolyte breakdown voltages ∼2 V, the maximum memory is ∼20 min at room temperature. The number of lines that could be sequentially matrix addressed in an electrochromic display matrix, under these conditions, spans the range 10–105, which encompasses any practical size of display matrices.
Outcomes of Surgical Treatment for Chronic Postoperative Breast and Abdominal Pain Attributed to the Intercostal Nerve (2006)

Operation appears to be a viable alternative for patients experiencing postoperative pain of the breast and abdomen from lesions of the intercostal nerve. Increased awareness of this diagnosis and the options for its management as presented in our algorithm should help to more quickly alleviate the pain of patients suffering from this disorder.
Novel Biologically Active Bibenzyls from Bauhinia saccocalyx Pierre (2004)

Four new bibenzyls, bauhinols A-D (1-4), together with the two known bibenzyls 5 and 6, were isolated from the roots of Bauhinia saccocalyx, and their structures were elucidated by analyses of spectroscopic data. Bauhinol A (1) exhibits significant cytotoxicity towards NCI-H187 (small-cell lung cancer), BC (breast cancer), and KB (oral-cavity cancer) cell lines, with IC50 values of 2.7-4.5 microg/ml. Bauhinol B (2) is cytotoxic against NCI-H187 (IC50 = 1.1 microg/ml) and BC (IC50 = 9.7 microg/ml) cell lines, but inactive toward the KB cell line (at 20 microg/ml). Compound 2 also is mildly antifungal towards Candia albicans (IC50 = 28.9 microg/ml). Bibenzyl 6 is active against NCI-H187 (IC50 = 14.1 microg/ml) and BC (IC50 = 4.0 microg/ml) cells, but inactive (at 20 microg/ml) toward the KB cell line. Compounds 1, 2, and 6 show mild antimycobacterial activities, with MIC values of 25-50 microg/ml, but are inactive at 20 microg/ml against the K1 malarial parasite strain (Plasmodium falciparum). While bauhinol A (1) is inactive against cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2), compounds 2 and 6 inhibit both COX-1 and COX-2, with IC50 values comparable to those of the standard drug, aspirin (Table 3).
FLAP COMPLICATIONS ASSOCIATED WITH LAMELLAR REFRACTIVE SURGERY (2000)

Abstract PURPOSE: Corneal lamellar refractive surgery for myopia reduces the risk of corneal haze but adds to the risk of flap complications. We retrospectively determined the incidence of flap complications in the initial series of eyes undergoing lamellar refractive surgery by one surgeon. We assessed the incidence of flap complications overall, the trend in these complications during the surgeon's learning curve, and the impact of the complications on best spectacle-corrected visual acuity. METHODS: Charts of the first 1,019 eyes that underwent myopic keratomileusis in situ or laser in situ keratomileusis were reviewed for flap complications and visual outcome. RESULTS: Of the 1,019 eyes, 490 eyes underwent myopic keratomileusis in situ, and 529 eyes underwent laser in situ keratomileusis. Eighty-eight (8.6%) of 1,019 eyes had flap-related complications. Six eyes had two complications. Intraoperative complications included irregular keratectomy in nine eyes (0.9%), incomplete keratectomy in three eyes (0.3%), and a free cap in 10 eyes (1.0%). The incidence of intraoperative complications was six (6.0%) in the first 100 consecutive eyes, 14 (2.3%) in the next 600 consecutive eyes ( P = .04, chi-square test), and one (0.3%) in the last 300 eyes ( P = .03, chi-square test). Postoperative complications included displaced flaps that required repositioning in 20 eyes (2.0%), folds in the flap that required repositioning in 11 eyes (1.1%), diffuse lamellar keratitis in 18 eyes (1.8%), infectious keratitis in one eye (0.1%), and epithelial ingrowth that required removal in 22 eyes (2.2%). The incidence of flap displacement and folds in 200 eyes in which we irrigated under the flap and allowed it to settle without further manipulation averaged 8.5%, whereas the incidence in other groups of 100 consecutive eyes averaged 0.8% ( P P = .0003, chi-square test). No eye lost 2 or more lines of best spectacle-corrected visual acuity because of flap complications. CONCLUSION: Flap complications after lamellar refractive surgery are relatively common but rarely lead to a permanent decrease in visual acuity. Physician experience with the microkeratome and with the handling of the corneal flap decreases the incidence of flap complications.
Primary Graft Function, Metabolic Control, and Graft Survival After Islet Transplantation (2009)

OBJECTIVE To investigate the influence of primary graft function (PGF) on graft survival and metabolic control after islet transplantation with the Edmonton protocol. RESEARCH DESIGN AND METHODS A total of 14 consecutive patients with brittle type 1 diabetes were enrolled in this phase 2 study and received median 12,479 islet equivalents per kilogram of body weight (interquartile range 11,072-15,755) in two or three sequential infusions within 67 days (44-95). PGF was estimated 1 month after the last infusion by the beta-score, a previously validated index (range 0-8) based on insulin or oral treatment requirements, plasma C-peptide, blood glucose, and A1C. Primary outcome was graft survival, defined as insulin independence with A1C < or =6.5%. RESULTS All patients gained insulin independence within 12 days (6-23) after the last infusion. PGF was optimal (beta-score > or =7) in nine patients and suboptimal (beta-score < or =6) in five. At last follow-up, 3.3 years (2.8-4.0) after islet transplantation, eight patients (57%) remained insulin independent with A1C < or =6.5%, including seven patients with optimal PGF (78%) and one with suboptimal PGF (20%) (P = 0.01, log-rank test). Graft survival was not significantly influenced by HLA mismatches or by preexisting islet autoantibodies. A1C, mean glucose, glucose variability (assessed with continuous glucose monitoring system), and glucose tolerance (using an oral glucose tolerance test) were markedly improved when compared with baseline values and were significantly lower in patients with optimal PGF than in those with suboptimal PGF. CONCLUSIONS Optimal PGF was associated with prolonged graft survival and better metabolic control after islet transplantation. This early outcome may represent a valuable end point in future clinical trials.
An overlay MAC layer for 802.11 networks (2005)

The widespread availability of 802.11-based hardware has made it the premier choice of both researchers and practitioners for developing new wireless networks and applications. However, the ever increasing set of demands posed by these applications is stretching the 802.11 MAC protocol beyond its intended capabilities. For example, 802.11 provides no control over allocation of resources, and the default allocation policy is ill-suited for heterogeneous environments and multi-hop networks. Fairness problems are further exacerbated in multi-hop networks due to link asymmetry and hidden terminals. In this paper, we take a first step towards addressing these problems without replacing the MAC layer by presenting the design and the implementation of an Overlay MAC Layer (OML), that works on top of the 802.11 MAC layer. OML uses loosely-synchronized clocks to divide the time in to equal size slots, and employs a distributed algorithm to allocate these slots among competing nodes. We have implemented OML in both a simulator and on a wireless testbed using the Click modular router. Our evaluation shows that OML can not only provide better flexibility but also improve the fairness, throughput and predictability of 802.11 networks.
Nonsense-Mediated mRNA Decay Factors, UPF1 and UPF3, Contribute to Plant Defense (2011)

In Arabidopsis, the NMD-defective mutants upf1-5 and upf3-1 are characterized by dwarfism, curly leaves and late flowering. These phenotypes are similar to those of mutants showing constitutive pathogenesis-related (PR) gene expression, salicylic acid (SA) accumulation and, subsequently, resistance to pathogens. The disease symptoms of upf1-5 and upf3-1 mutants were observed following infection with the virulent pathogen Pst DC3000 with the aim of determining whether the loss of nonsense-mediated mRNA decay (NMD) is involved in disease resistance. These mutant plants showed not only enhanced resistance to Pst DC3000, but also elevated levels of endogenous SA, PR gene transcripts and WRKY transcripts. UPF1 and UPF3 expression was down-regulated in Pst DC3000-infected Arabidopsis plants, but the expression of various NMD target genes was up-regulated. The expression of 10 defense-related genes was elevated in cycloheximide (CHX)-treated plants. The transcriptional ratios of eight of these 10 defense-related genes in CHX-treated to non-treated plants were lower in NMD-defective mutants than in the wild-type plants. These eight defense-related genes are possibly regulated by the NMD mechanism, and it is clear that an alternatively spliced transcript of WRKY62, which contains a premature termination codon, was regulated by this mechanism. Taken together, our results suggest that UPF1 and UPF3, which are key NMD factors, may act as defense-related regulators associated with plant immunity.
I Reunión Post-European Headache Federation: revisión de las novedades presentadas en el Congreso de la European Headache Federation de 2020 (2021)

Introduction. After the European Headache Federation (EHF) Congress, renowned Spanish neurologists specialised in migraine presented the most significant latest developments in research in this field at the Post-EHF Meeting. Development. The main data presented concerning the treatment of chronic and episodic migraine were addressed, with attention paid more specifically to those related to preventive treatments and real-life experience in the management of the disease. An important review was carried out of the new therapeutic targets and the possibilities they offer in terms of understanding the pathophysiology of migraine and its treatment. An update was also presented of the latest developments in the treatment of migraine with fremanezumab, a monoclonal antibody recently authorised by the European Medicines Agency. Participants were also given an update on the latest developments in basic research on the pathology, as well as an overview of the symptoms of migraine and COVID-19. Finally, the repercussions of migraine in terms of its burden on the care and economic resources of the health system were addressed, along with its impact on society. Conclusions. The meeting summarised the content presented at the 14<sup>th</sup> EHF Congress, which took place in late June/early July 2020.
The intravenous and oral pharmacokinetics of afoxolaner and milbemycin oxime when used as a combination chewable parasiticide for dogs (2016)

The pharmacokinetics of afoxolaner and milbemycin oxime (A3 and A4 forms) in dogs were evaluated following the oral administration of NexGard Spectra<sup>®</sup> (Merial), a fixed combination chewable formulation of these two active pharmaceutical ingredients. Absorption of actives was rapid at levels that provide the minimum effective doses of 2.5 mg/kg and 0.5 mg/kg of afoxolaner and milbemycin oxime, respectively. The time to maximum afoxolaner plasma concentrations (t<sub>max</sub> ) was 2-4 h. The milbemycin t<sub>max</sub> was 1-2 h. The terminal plasma half-life (t<sub>1/2</sub> ) and the oral bioavailability were 14 ± 3 days and 88.3% for afoxolaner, 1.6 ± 0.4 days and 80.5% for milbemycin oxime A3 and 3.3 ± 1.4 days and 65.1% for milbemycin oxime A4. The volume of distribution (V<sub>d</sub> ) and systemic clearance (Cls) were determined following an IV dose of afoxolaner or milbemycin oxime. The V<sub>d</sub> was 2.6 ± 0.6, 2.7 ± 0.4 and 2.6 ± 0.6 L/kg for afoxolaner, milbemycin oxime A3 and milbemycin oxime A4, respectively. The Cls was 5.0 ± 1.2, 75 ± 22 and 41 ± 12 mL/h/kg for afoxolaner, milbemycin oxime A3 and milbemycin oxime A4, respectively. The pharmacokinetic profile for the combination of afoxolaner and milbemycin oxime supports the rapid onset and a sustained efficacy for afoxolaner against ectoparasites and the known endoparasitic activity of milbemycin oxime.
Continuous Chromatography as a Fully Integrated Process in Continuous Biomanufacturing (2017)

Chromatography is the main working horse in the separation of biomolecules. Beside continuous chromatography, there are several unit operations that can be very beneficial, especially in continuous downstream. This is, for example, the case for aqueous two-phase liquid extraction in the downstream of monoclonal antibodies (mAb). Hence, all unit operations should be taken into account when developing a new biotechnological process. The fully continuous simulated moving bed (SMB) is capable of continuous loading and continuous product elution. It is not well suited for the resins typically used in biotechnological processing. For continuous loading and better resin utilization, the sequential column setups such as sequential multicolumn chromatography (SMCC), periodic countercurrent chromatography (PCC), or BioSMB are a good choice. The more innovative approach is the twin-column multicolumn countercurrent solvent gradient purification (MCSGP) or iCCC. These not only achieve better resin utilization but also enhance the whole separation in terms of purity and yield.
Proteomic Analysis Reveals Drug Accessible Cell Surface N-Glycoproteins of Primary and Established Glioblastoma Cell Lines (2012)

Glioblastoma is the most common primary brain tumor in adults with low average survival time after diagnosis. In order to improve glioblastoma treatment, new drug-accessible targets need to be identified. Cell surface glycoproteins are prime drug targets due to their accessibility at the surface of cancer cells. To overcome the limited availability of suitable antibodies for cell surface protein detection, we performed a comprehensive mass spectrometric investigation of the glioblastoma surfaceome. Our combined cell surface capturing analysis of primary ex vivo glioblastoma cell lines in combination with established glioblastoma cell lines revealed 633 N-glycoproteins, which vastly extends the known data of surfaceome drug targets at subcellular resolution. We provide direct evidence of common glioblastoma cell surface glycoproteins and an approximate estimate of their abundances, information that could not be derived from genomic and/or transcriptomic glioblastoma studies. Apart from our pharmaceutically valuable repertoire of already and potentially drug-accessible cell surface glycoproteins, we built a mass-spectrometry-based toolbox enabling directed, sensitive, and repetitive glycoprotein measurements for clinical follow-up studies. The included Skyline Glioblastoma SRM assay library provides an elevated starting point for parallel testing of the abundance level of the detected glioblastoma surfaceome members in future drug perturbation experiments.
An engineering research testbed for photovoltaics (1999)

The Ohio Aerospace Institute and the NASA Lewis Research Center are designing and building a solar-cell calibration facility, the Photovoltaic Engineering Testbed (PET) to fly on the International Space Station to calibrate, measure, and qualify advanced solar cell types in the space environment. PET will serve three primary functions: calibration, measurement, and qualification of solar cells, in order to bring new solar cell technologies to spaceflight readiness.
Different coordination modes of neutral and deprotonated ZC(S)N(H)R ligands (Z = PPh2, R = Ph, Me; Z = NMe2, R = Ph) in molybdenum and tungsten complexes. X-ray structure analysis of [Mo(CO)2[Ph2PC(S)NMe][.mu.-Ph2PC(S)NMe]]2.CH2Cl2 (1984)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTDifferent coordination modes of neutral and deprotonated ZC(S)N(H)R ligands (Z = PPh2, R = Ph, Me; Z = NMe2, R = Ph) in molybdenum and tungsten complexes. X-ray structure analysis of [Mo(CO)2[Ph2PC(S)NMe][.mu.-Ph2PC(S)NMe]]2.CH2Cl2H. P. M. M. Ambrosius, J. Willemse, J. A. Cras, W. P. Bosman, and J. H. NoordikCite this: Inorg. Chem. 1984, 23, 17, 2672–2678Publication Date (Print):August 1, 1984Publication History Published online1 May 2002Published inissue 1 August 1984https://pubs.acs.org/doi/10.1021/ic00185a025https://doi.org/10.1021/ic00185a025research-articleACS PublicationsRequest reuse permissionsArticle Views38Altmetric-Citations10LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-AlertscloseSupporting Info (1)»Supporting Information Supporting Information Get e-Alerts
Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications (2022)

For nearly 50 years the proximal tubule (PT) has been known to reabsorb, process, and either catabolize or transcytose albumin from the glomerular filtrate. Innovative techniques and approaches have provided insights into these processes. Several genetic diseases, nonselective PT cell defects, chronic kidney disease (CKD), and acute PT injury lead to significant albuminuria, reaching nephrotic range. Albumin is also known to stimulate PT injury cascades. Thus, the mechanisms of albumin reabsorption, catabolism, and transcytosis are being reexamined with the use of techniques that allow for novel molecular and cellular discoveries. Megalin, a scavenger receptor, cubilin, amnionless, and Dab2 form a nonselective multireceptor complex that mediates albumin binding and uptake and directs proteins for lysosomal degradation after endocytosis. Albumin transcytosis is mediated by a pH-dependent binding affinity to the neonatal Fc receptor (FcRn) in the endosomal compartments. This reclamation pathway rescues albumin from urinary losses and cellular catabolism, extending its serum half-life. Albumin that has been altered by oxidation, glycation, or carbamylation or because of other bound ligands that do not bind to FcRn traffics to the lysosome. This molecular sorting mechanism reclaims physiological albumin and eliminates potentially toxic albumin. The clinical importance of PT albumin metabolism has also increased as albumin is now being used to bind therapeutic agents to extend their half-life and minimize filtration and kidney injury. The purpose of this review is to update and integrate evolving information regarding the reabsorption and processing of albumin by proximal tubule cells including discussion of genetic disorders and therapeutic considerations.